[{"address1": "1201 Orange Street", "address2": "Suite 600", "city": "Wilmington", "state": "DE", "zip": "19801", "country": "United States", "phone": "484 254 6134", "website": "https://www.nrxpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan C. Javitt M.D., M.P.H.", "age": 67, "title": "Co-Founder, Chief Scientist Officer, Chairman & Interim CEO", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 825000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Patrick Duffy", "age": 61, "title": "Chief Business Officer & Co-CEO of Hope Therapeutics", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 338000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael S. Abrams", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Riccardo  Panicucci Ph.D.", "age": 63, "title": "Chief Manufacturing & Technology Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 240000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Suzanne  Messere", "title": "Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philip T. Lavin Ph.D.", "age": 77, "title": "Chief Methodologist", "yearBorn": 1947, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.3200002, "open": 3.3, "dayLow": 3.215, "dayHigh": 3.39, "regularMarketPreviousClose": 3.3200002, "regularMarketOpen": 3.3, "regularMarketDayLow": 3.215, "regularMarketDayHigh": 3.39, "payoutRatio": 0.0, "beta": 1.548, "forwardPE": -2.6614175, "volume": 93865, "regularMarketVolume": 93865, "averageVolume": 260678, "averageVolume10days": 225090, "averageDailyVolume10Day": 225090, "bid": 3.36, "ask": 3.41, "bidSize": 1, "askSize": 1, "marketCap": 65921496, "fiftyTwoWeekLow": 1.1, "fiftyTwoWeekHigh": 6.01, "fiftyDayAverage": 2.73678, "twoHundredDayAverage": 2.192945, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 59211764, "profitMargins": 0.0, "floatShares": 13364027, "sharesOutstanding": 19503400, "sharesShort": 1196888, "sharesShortPriorMonth": 1111671, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.0692, "heldPercentInsiders": 0.15883, "heldPercentInstitutions": 0.13077, "shortRatio": 2.66, "shortPercentOfFloat": 0.077199996, "impliedSharesOutstanding": 19503400, "bookValue": -1.47, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -24110000, "trailingEps": -1.96, "forwardEps": -1.27, "lastSplitFactor": "1:10", "lastSplitDate": 1712016000, "enterpriseToEbitda": -3.394, "52WeekChange": 0.45689654, "SandP52WeekChange": 0.12677538, "quoteType": "EQUITY", "currentPrice": 3.38, "targetHighPrice": 46.0, "targetLowPrice": 18.0, "targetMeanPrice": 31.66667, "targetMedianPrice": 31.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 5548000, "totalCashPerShare": 0.321, "ebitda": -17447750, "totalDebt": 8397000, "quickRatio": 0.169, "currentRatio": 0.222, "returnOnAssets": -1.91741, "freeCashflow": 3231875, "operatingCashflow": -10446000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "NRXP", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1751574882, "regularMarketTime": 1751562000, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1512397800000, "shortName": "NRX Pharmaceuticals, Inc.", "longName": "NRx Pharmaceuticals, Inc.", "exchange": "NCM", "messageBoardId": "finmb_319388181", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 1.80723, "regularMarketPrice": 3.38, "postMarketChangePercent": 0.0, "postMarketPrice": 3.38, "postMarketChange": 0.0, "regularMarketChange": 0.0599999, "regularMarketDayRange": "3.215 - 3.39", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 260678, "fiftyTwoWeekLowChange": 2.2800002, "fiftyTwoWeekLowChangePercent": 2.0727274, "fiftyTwoWeekRange": "1.1 - 6.01", "fiftyTwoWeekHighChange": -2.63, "fiftyTwoWeekHighChangePercent": -0.437604, "fiftyTwoWeekChangePercent": 45.689655, "earningsTimestampStart": 1755115200, "earningsTimestampEnd": 1755115200, "earningsCallTimestampStart": 1742214600, "earningsCallTimestampEnd": 1742214600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.96, "epsForward": -1.27, "epsCurrentYear": 0.15, "priceEpsCurrentYear": 22.533333, "fiftyDayAverageChange": 0.6432202, "fiftyDayAverageChangePercent": 0.2350281, "twoHundredDayAverageChange": 1.1870551, "twoHundredDayAverageChangePercent": 0.5413064, "priceToBook": -2.2993197, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.0 - Strong Buy", "marketState": "CLOSED", "displayName": "NRx Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-07-05"}]